跳至主要内容
临床试验/NCT03675932
NCT03675932已完成不适用

Rapid Cadence Cycling for Parkinson's Disease: A Study of Implementation and Efficacy in the Community Setting

Massachusetts General Hospital2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2018年10月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
24
试验地点
2
主要终点
Percentage of individuals who complete at least 80% of offered cycling sessions [Tolerability]

研究概览

简要总结

Forced cadence cycling (FCC) in which individuals with Parkinson's Disease (PD) pedal with external augmentation at 80-90 revolutions per minute (rpm) has demonstrated significant motor improvement in prior clinical trials. These studies required either a tandem bicycle with second rider or an expensive motorized bicycle, making this therapy inaccessible to most patients. In this pragmatic open-label before and after pilot study investigators examine implementation and effectiveness of (RCC) without tandem or motor augmentation and in a community-based setting. Approximately 30 participants will be recruited to participate in 24 one-hour rapid-cadence spin classes in YMCAs over 8 weeks. Primary outcomes will examine implementation of the intervention and secondary outcomes will examine effectiveness against a historical comparison group.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults age 18 or older.
  • Clinically confirmed diagnosis of idiopathic PD by a movement disorder specialist.
  • Hoehn and Yahr stage I-III while ON anti-parkinsonian medication.
  • Stable or absent MAO-B inhibitors (Selegiline, Rasagiline, Zydis selegiline HCL Oral disintegrating) for at least 60 days prior to enrollment; stable or absent other medications for PD motor symptoms (Levodopa, Dopamine agonists, Anticholinergics, Amantadine, COMT-Inhibitors) for at least 30 days prior to enrollment; stable or absent medications for the following PD-non-motor symptoms: depression, anxiety, cognition, sleep, orthostatic hypotension.
  • Agreement to defer any medication changes until after completion of 8-week program and post-test measurements.
  • Written permission by a physician to participate in the program.
  • English language proficiency sufficient to understand and participate in a cycling class taught in English.

排除标准

  • Clinically significant medical disease that would increase the risk of exercise-related complications (eg: cardiac or pulmonary disease, uncontrolled diabetes mellitus, uncontrolled hypertension or stroke) as determined by a treating physician through letter obtained by YMCA or the study investigator.
  • Dementia as evidenced by a score of less than 116 on the Mattis Dementia Rating Scale or dementia in the opinion of the study investigator that would prohibit subject from complying with all study activities.
  • Other medical or musculoskeletal contraindication to exercise.
  • Concurrent participation in another trial of exercise therapy for PD or initiation of a new structured exercise plan during the duration of the study. Note: participants may continue any pre-existing exercise routine (including group-based classes) during the study but will be asked not to start anything new.

结局指标

主要结局

Percentage of individuals who complete at least 80% of offered cycling sessions [Tolerability]

时间窗: assessed at conclusion of the 8 week intervention

Investigators will consider those who do not withdraw from the study, are not lost to follow up, and complete at least 80% of the cycling sessions to demonstrate tolerability of the study.

Proportion of subjects reporting an adverse event during class [Safety]

时间窗: assessed at each class by study staff and weekly by PI for duration of 8 week intervention

Safety will be reported descriptively and include the proportion of subjects reporting any adverse event.

次要结局

  • Modified Unified Parkinson's Disease Rating Scale-section III Motor(Assessed within two weeks prior to start of intervention and within one week after completion of intervention)
  • Assessment of Intelligibility of Dysarthria (AIDS)(Assessed within two weeks prior to start of intervention and within one week after completion of intervention)
  • Timed Up and Go(Assessed within two weeks prior to start of intervention and within one week after completion of intervention)
  • Trail Making Test A& B(Assessed within two weeks prior to start of intervention and within one week after completion of intervention)
  • PROMIS sf v1.0 Global Health(Assessed within two weeks prior to start of intervention and within one week after completion of intervention)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Anne-Marie Alexandra Wills, MD

Assistant Professor in Neurology

Massachusetts General Hospital

研究点 (2)

Loading locations...

相似试验